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Objective: To investigate the guiding role of pharmaceutical care in the 
treatment of bronchial asthma. Methods: Eighty patients with bronchi-
al disease admitted to our hospital from November 2008 to December 
1818 were enrolled in this research. The computer program was used 
to generate random numbers. The method was divided into two groups: 
control group and observation group, 40 cases respectively. 40 patients in 
the control group were treated with normal medication according to the 
doctor’s advice; 40 patients in the observation group were enrolled in the 
pharmacological care on the basis of the control group, and the rational 
drug use was compared between the two groups. Results: The incidence 
of adverse reactions in the observation group and the control group were 
5.00% and 17.50%, respectively, and the difference was statistically sig-
nificant (P<0.05); the incidence of medication error events in the obser-
vation group was 7.50%, which was significantly lower than that of the 
control group, which was 25.00%, and the difference was statistically sig-
nificant (P<0.05). The medication errors mainly include improper admin-
istration, incorrect dosage, and unscientific administration. Conclusion: 
The guiding role of pharmaceutical care in bronchial asthma rational 
drug use can reduce medication error events and ensure rational drug use, 
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1. Introduction
Bronchial asthma is a common chronic respiratory disease in the clinic. In recent years, it has been affected by the living environment, and the num-
ber of people with the disease is increasing. There is no 
cure at all, but long-term medication can control acute 
asthma attacks [1,2], improve performance symptoms and 
prevent irreversible airflow limitation. There are many 
types of drugs for clinical treatment of bronchial asthma, 
and there are differences in the way of administration. 
The wrong way of using drugs can not only alleviate the 
condition, but also delay the treatment of patients. Phar-
maceutical care mainly refers to providing patients with 
direct and responsible care related to pharmacy [3,4]. In 
bronchial asthma, clinical pharmacists participate in the 
treatment of asthma, and guide patients to more rational 
drug use. To further accurately evaluate the guiding role 
of pharmaceutical care in the rational drug use of bronchi-
al asthma, this research selected 80 patients with bronchial 
asthma in our hospital, as reported below.
24
Journal of Integrative Medicine | Volume 08 | Issue 01 | June 2019
Distributed under creative commons license 4.0
2. Data and Methods
2.1 Clinical Data
This paper selected 80 patients with bronchial asthma 
treated in our hospital. All cases were diagnosed by patho-
logical examination, which showed symptoms such as 
cough and wheezing. The computer program was used to 
generate random numbers. The method was divided into 
observation group and control group, 40 cases in each 
group. The observation group patients ranged in age from 
22 to 73 years, including male to female ratio of 22:18 
and average age of (60.72±2.63) years old. The control 
group was 21 to 72 years old, with a male to female ratio 
of 23:17 and an average age of (60.48±2.71) years old. 
Exclusion criteria: (1) those who are allergic to selected 
drugs; (2) those with abnormal organs such as heart, liver 
and kidney; (3) women during pregnancy and lactation; (4) 
those who did not sign the informed consent form. There 
was no statistically significant difference between the two 
groups (P>0.05), which was comparable.
2.2 Methods
The patients in the control group were given normal med-
ication according to the doctor’s advice; the patients in 
the observation group were added pharmacological care 
on the basis of the control group. The specific operation 
methods are as follows:
(1) Inquire About the Patient’s Past Medical History 
and Do a Physical Examination
The doctor and the pharmacist understand the patient’s 
body condition based on the patient’s medical history and 
allergic history, comprehensively analyze the patient’s 
liver and kidney function test results, and formulate a 
reasonable medication plan to ensure rationalization and 
compliance with the “Bronchial Asthma Diagnosis and 
Treatment Guidelines”.
(2) Pharmaceutical Care during Treatment
Patients taking glucocorticoids should pay attention 
to adverse reactions such as increased blood pressure, 
hypokalemia and osteoporosis, and patients with hyper-
tension should reduce the dose of the drug appropriate-
ly; inhaled glucocorticoid therapy Chinese pharmacists 
should guide patients to master the inhalation method, 
and then gargle in time to prevent pharyngeal infection of 
Candida; doxofylline can directly act on the bronchus, so 
the pharmacist should pay attention to the infusion rate of 
doxofylline injection. If the drug is administered too fast, 
patients may easily develop nausea, vomiting, arrhythmia 
and other symptoms [5,6], therefore, nurses are expected to 
be reminded that the initial infusion rate should be slowed 
down, and the blood concentration of theophylline should 
be monitored to avoid theophylline poisoning.
(3) Do a Good Job in the Publicity and Education of 
Rational Drug Use
The pharmacist should take the initiative to explain 
to the patient the dosage, usage and time interval of the 
drug, to ensure the scientificity of the drug, and to use the 
drug according to the standard time, so that the patient 
understands the importance of correct drug use, espe-
cially the drug in the inhalation device, and the patient 
should master the correct method of use. In the treatment 
of bronchial asthma, closely monitor the patient’s body 
state, and check the blood pressure, blood sugar and other 
indicators. If there is any abnormality and contact with the 
attending doctor in time, the patient will come to the hos-
pital for regular review and adjust the dosage according to 
the change of the symptoms of bronchial asthma.
2.3 Observation Indicators and Judgment Stan-
dards
The adverse reactions of the two groups of patients and 
the incidence of medication errors were compared.
2.4 Statistical Processing
The data collected by the specialists were collected and 
processed into the statistical software SPSS17.0. The stan-
dard deviation ( sx ± ) represents the measurement data, 
t-test; % represents the count data, x2 verification, P < 0.05 
means statistically significant.
3. Results
3.1 Comparison of Adverse Reactions between the 
Two Groups of Patients
The incidence of adverse reactions in the observation 
group and the control group were 5.00% and 17.50%, re-
spectively, and the difference was statistically significant 
(P<0.05), see Table 1 for details.
Table 1. Comparison of adverse reactions between the 
two groups of patients (Cases, %)






Group 40 1 (2.50) 0 1 (2.50) 5.00
Control 
Group 40 3 (7.50) 2 (5.00) 2 (5.00) 17.50
3.2 Comparison of the Incidence Rate of Medi-
cation Error Events between the Two Groups of 
Patients
The incidence of medication error events in the obser-
DOI: https://doi.org/10.30564/jim.v8i1.991
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vation group was 7.50%, which was significantly lower 
than that of the control group, which was 25.00%, and the 
difference was statistically significant (P<0.05). The med-
ication errors mainly include improper drug combination, 
incorrect method & dosage, and unscientific drug delivery 
method, etc., see Table 2 for details.
Table 2. Comparison of the incidence rate of medication 
error events between the two groups of patients (Cases, %)













tion Group 40 1 (2.50) 1 (2.50) 1 (2.50) 7.50
Control 
Group 40 3 (7.50) 3 (7.50) 4 (10.00) 25.00
4. Discussion
The guiding role of pharmaceutical care is increasingly 
valued by clinical research, especially in the treatment of 
bronchial asthma patients, because of the complexity of 
the mode of administration and dosage. Therefore, it is 
prone to the phenomenon that the patient does not have a 
rational drug use and affects the therapeutic effect. There-
fore, the pharmacist should strengthen the knowledge and 
education of the drug before the patient receives treatment 
[7,8], detail the knowledge about bronchial asthma attack, 
improve the patient’s medication compliance, let the pa-
tient prepare psychologically, and adhere to long-term 
regular drug treatment, and effectively control the prog-
ress of the disease. Pharmaceutical care can guide patients 
to treat children with diseases and reduce their psycho-
logical burden. Information such as the type of bronchial 
asthma, severity of illness, and level of control can affect 
rational drug use. Therefore, according to the changes 
in the condition, the drug selection in the drug treatment 
plan is upgraded or lowered, and a single treatment plan 
and form are avoided [9,10], and the graded treatment plan 
is made clear. At the same time, the pharmaceutical care 
executive pharmacist should check the patient’s general 
information and past medical history in advance, and 
consider the patient’s personal situation when selecting 
the treatment drug, such as whether to combine chronic 
disease, cardiovascular disease, etc., whether there is any 
possible adverse reaction after using the drug. The phar-
maceutical care focuses on the consultation of patients 
with medication, so the clinical rational drug use is the 
goal of the pharmacist to perform pharmaceutical care, to 
minimize the use of medication errors, and to guide the 
combination of medication, mode of administration and 
dosage of bronchial asthma patients.
The results of this research showed that from the ad-
verse reactions and medication errors, the observation 
group was lower than the control group, the difference 
was statistically significant (P <0.05), confirming that 
pharmaceutical care plays an active role in guiding the ra-
tional drug use of bronchial asthma patients. Pharmacists 
provide comprehensive and thoughtful services to patients 
through pharmaceutical care, timely discover the unrea-
sonableness of patients’ medications, and deepen their 
familiarity with drugs [11,12], therefore, clinical pharmacists 
should have a high level of professionalism and system-
atic expertise, and be able to introduce patients and their 
families with disease knowledge and medication problems 
in detail, not only to enhance the knowledge of patients 
and their families on disease knowledge, but also to re-
duce medication errors. Bronchial asthma is an allergic 
disease characterized by long-term, recurrent episodes. If 
there is an infection, it is necessary to combine antibiotic 
treatment. It is necessary for the clinical pharmacist to 
remove unnecessary antibiotics according to the patient’s 
personal situation and improve the patient’s ability to re-
spond to adverse drug reactions, and explain in detail the 
treatment of bronchial asthma patients often used in the 
type of drugs, usage, precautions, effects and adverse re-
actions [13,14], to ensure the effective control. In the results 
of this research, the observation group was enrolled in 
pharmaceutical care under the doctor’s advice, and the in-
cidence of adverse reactions to the doctor’s routine in the 
control group was lower, and the medication error event 
was reduced. In the diagnosis process of bronchial asthma, 
the patient’s lung function is taken as the standard, and 
the patient’s lung function is reviewed regularly to better 
understand the changes of lung function at any time, so as 
to provide reference for clinical treatment. The physician 
and the pharmacist adjust the patient’s treatment plan ac-
cording to the changes of the patient’s lung function, to 
ensure the rationality of medication.
5. Conclusion
In summary, the guiding role of pharmaceutical care in 
bronchial asthma medication use can reduce medication 
error events and ensure rational drug use, which is worthy 
of popularization in clinical practice.
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